Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Raw Materials (2016 - 2025)

Historic Raw Materials for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $32.8 million.

  • Heron Therapeutics' Raw Materials rose 5746.12% to $32.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 5746.12%. This contributed to the annual value of $19.7 million for FY2024, which is 1184.61% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Raw Materials is $32.8 million, which was up 5746.12% from $35.8 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Raw Materials high stood at $35.8 million for Q2 2025, and its period low was $15.1 million during Q4 2022.
  • For the 5-year period, Heron Therapeutics' Raw Materials averaged around $21.0 million, with its median value being $19.7 million (2024).
  • Per our database at Business Quant, Heron Therapeutics' Raw Materials plummeted by 3602.48% in 2023 and then surged by 8279.58% in 2025.
  • Quarter analysis of 5 years shows Heron Therapeutics' Raw Materials stood at $21.2 million in 2021, then fell by 28.58% to $15.1 million in 2022, then grew by 16.56% to $17.6 million in 2023, then increased by 11.85% to $19.7 million in 2024, then skyrocketed by 66.14% to $32.8 million in 2025.
  • Its last three reported values are $32.8 million in Q3 2025, $35.8 million for Q2 2025, and $19.5 million during Q1 2025.